BACKGROUND: Breakthrough coronavirus disease 2019 (COVID-19) may occur in fully vaccinated persons. METHODS: We assessed the clinical outcomes of breakthrough COVID-19 in fully vaccinated individuals. RESULTS: In this cohort of 1395 persons (mean age, 54.3 years; 60% female; median body mass index, 30.7) who developed breakthrough COVID- 19, there were 107 (7.7%) who required hospitalization by day 28. Hospitalization was significantly associated with the number of medical comorbidities. Antispike monoclonal antibody treatment was significantly associated with a lower risk of hospitalization (odds ratio, 0.227; 95% confidence interval, 0.128-0.403; P < .001). The number needed to treat (NNT) to prevent 1 hospitalization was 225 among the lowest risk patient group compared with NNT of 4 among those with highest numbers of medical comorbidity. CONCLUSIONS: Monoclonal antibody treatment is associated with reduced hospitalization in vaccinated high-risk persons with mild to moderate COVID-19.
BACKGROUND: Breakthrough coronavirus disease 2019 (COVID-19) may occur in fully vaccinated persons. METHODS: We assessed the clinical outcomes of breakthrough COVID-19 in fully vaccinated individuals. RESULTS: In this cohort of 1395 persons (mean age, 54.3 years; 60% female; median body mass index, 30.7) who developed breakthrough COVID- 19, there were 107 (7.7%) who required hospitalization by day 28. Hospitalization was significantly associated with the number of medical comorbidities. Antispike monoclonal antibody treatment was significantly associated with a lower risk of hospitalization (odds ratio, 0.227; 95% confidence interval, 0.128-0.403; P < .001). The number needed to treat (NNT) to prevent 1 hospitalization was 225 among the lowest risk patient group compared with NNT of 4 among those with highest numbers of medical comorbidity. CONCLUSIONS: Monoclonal antibody treatment is associated with reduced hospitalization in vaccinated high-risk persons with mild to moderate COVID-19.
Authors: Raymund R Razonable; John C O'Horo; Douglas W Challener; Lori Arndt; Richard F Arndt; Caroline G Clune; Tracy L Culbertson; Scott T Hall; Alexander Heyliger; Tammy A Jackson; Brian D Kennedy; Jennifer Larsen; Sara N Hanson; Perry W Sweeten; Sidna M Tulledge-Scheitel; Ravindra Ganesh Journal: Mayo Clin Proc Date: 2022-06-23 Impact factor: 11.104
Authors: Mohanad M Al-Obaidi; Ahmet B Gungor; Saman Nematollahi; Tirdad T Zangeneh; Edward J Bedrick; Katherine M Johnson; Nicole E Low-Adegbija; Ruhaniyah Alam; Pooja Rangan; C William Heise; Venkatesh K Ariyamuthu; Aneesha Shetty; Abd Assalam Qannus; Sangeetha Murugapandian; Mehmet M S Ayvaci; Prince Mohan Anand; Bekir Tanriover Journal: Open Forum Infect Dis Date: 2022-04-12 Impact factor: 4.423
Authors: Todd C Lee; Andrew M Morris; Steven A Grover; Srinivas Murthy; Emily G McDonald Journal: Open Forum Infect Dis Date: 2022-01-19 Impact factor: 3.835
Authors: Annika Fendler; Elisabeth G E de Vries; Corine H GeurtsvanKessel; John B Haanen; Bernhard Wörmann; Samra Turajlic; Marie von Lilienfeld-Toal Journal: Nat Rev Clin Oncol Date: 2022-03-11 Impact factor: 65.011
Authors: Sean W X Ong; Dongdong Ren; Pei Hua Lee; Stephanie Sutjipto; Christopher Dugan; Bo Yan Khoo; Jun Xin Tay; Shawn Vasoo; Barnaby E Young; David C Lye Journal: Antibiotics (Basel) Date: 2022-03-05